Welcome to our dedicated page for Lite Strategy SEC filings (Ticker: LITS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lite Strategy, Inc. (LITS) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents explain how Lite Strategy reports its transition from MEI Pharma into a business that combines a Litecoin-focused digital asset treasury strategy with the management and potential monetization of legacy pharmaceutical assets.
Through Forms 8-K and related amendments, Lite Strategy describes material events such as its corporate name and ticker change, capital raising transactions, and governance changes. Filings detail the authorization and terms of private placement offerings, including pre-funded warrants, and subsequent exercises that impact the company’s capital structure. They also document the authorization of a share repurchase program, outlining how and under what conditions the company may repurchase its common stock.
Regulatory filings further cover board and executive matters, including director resignations, committee roles, and the appointment of the company’s Chief Financial Officer and Secretary as permanent Chief Executive Officer and board member. Associated equity compensation grants, such as stock options under the company’s omnibus equity plan and corrections to previously reported option awards, are described in detail, including vesting schedules and exercise prices.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items like executive compensation arrangements, capital markets transactions, and treasury-related decisions. Real-time updates from EDGAR ensure that new 8-Ks, registration-related filings, and other reports appear promptly, while AI-generated insights make it easier to interpret complex legal and financial language without reading every page.
Lite Strategy, Inc. (LITS) reported an equity award to one of its directors in the form of stock options. On 11/14/2025, the director received an option grant covering 55,000 shares of common stock at an exercise price of $2.02 per share. These options are a customary annual grant to non-employee directors and were received as compensation for board service. The options vest over time, with 16.66666% vesting on the grant date and the remaining portion vesting in equal monthly amounts beginning 12/14/2025 and continuing through 11/14/2026, encouraging ongoing alignment between the director’s interests and those of shareholders.
Lite Strategy, Inc. (LITS) reported that a non-employee director received stock option awards. On November 14, 2025, the director was granted a stock option to purchase 55,000 shares of common stock at an exercise price of $2.02 per share, exercisable through November 14, 2035. This grant is described as a customary annual award to non-employee directors and vests 16.66666% on the grant date, with the remainder vesting monthly from December 14, 2025 through November 14, 2026.
On the same date, the director also received a separate stock option for 10,000 shares of common stock at an exercise price of $2.02 per share, also expiring on November 14, 2035. This option is described as a customary grant upon appointment to the Board, as revised on November 14, 2025, and vests in 36 equal monthly installments beginning one month after the grant date, subject to continued service.
Lite Strategy, Inc. (LITS) reported that a non-employee director received a customary annual stock option grant. On 11/14/2025, the director was awarded options to purchase 55,000 shares of common stock at an exercise price of $2.02 per share as compensation for board service. The options vest over one year, with 16.66666% vesting on the grant date and the remaining options vesting in equal monthly amounts beginning 12/14/2025 and continuing through 11/14/2026. The options expire on 11/14/2035 and are held directly by the reporting person.
Lite Strategy, Inc. reported an insider equity award for its chief executive. A Form 4 shows that the CEO, CFO, Secretary and director received a stock option to buy 635,000 shares of common stock at an exercise price of $2.02 per share on 11/14/2025 as employment compensation. The option is scheduled to vest in 36 equal monthly installments, with the first installment vesting one month after the grant date, subject to continued service through each vesting date.
Lite Strategy, Inc. announced that its Board has appointed Justin J. File as permanent Chief Executive Officer and elected him to the Board of Directors, effective immediately. He will continue to serve as Chief Financial Officer and Secretary, consolidating the company’s top executive and financial roles under a single leader.
In connection with his promotion, Mr. File received stock options to purchase 635,000 shares of common stock at an exercise price of $2.02 per share, which was the closing price on the grant date. These options were issued under the company’s Amended and Restated 2008 Stock Omnibus Equity Compensation Plan and vest in 36 monthly installments starting December 14, 2025, with a 10-year term. Mr. File will not receive additional compensation for serving on the Board, and the company plans to enter into an addendum to his employment agreement to document the new terms.
Lite Strategy, Inc. (Nasdaq: LITS) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $3.6 million, a narrower loss than the $8.0 million in the prior year period, as operating expenses declined with R&D falling to $10 thousand and G&A to $3.1 million. A $0.6 million loss from change in fair value of digital assets was recognized.
Balance sheet strength shifted to digital assets. Cash and cash equivalents were $10.1 million, and Litecoin holdings were $99.4 million, reflecting 929,548 LTC acquired under the new Litecoin Treasury Strategy following a $100.0 million July 2025 PIPE. Total assets were $113.3 million and stockholders’ equity was $112.3 million.
Capital actions and liquidity. In July, the company issued 23.2 million common shares at $3.42 and pre-funded warrants in the PIPE, and raised an additional $4.6 million net via its ATM. Operating cash use was $4.5 million; $100.0 million was deployed to purchase LTC; financing provided $96.6 million. Subsequent to quarter-end, remaining PIPE pre-funded warrants were exercised and the Board authorized a $25.0 million share repurchase program.
Lite Strategy, Inc. (LITS) filed an 8-K announcing two items. First, Thomas C. Reynolds, M.D., Ph.D. notified the Board on October 24, 2025 of his decision to resign as a director, effective November 4, 2025. He will also step down from the Compensation Committee and the Nominating & Governance Committee. The company stated his resignation is not the result of any disagreement with operations, policies, or practices.
Second, the Board authorized a common stock repurchase program under which the company may purchase up to $25 million of its common stock, as announced via press release on October 29, 2025. Repurchases may occur in the open market, through privately negotiated transactions, or under Rule 10b5-1 plans, subject to market conditions, applicable law, and other factors. The program does not obligate any repurchases and may be suspended or discontinued at any time.
MEI Pharma, Inc. filed a shelf registration on Form S-3 that describes the company's capitalization and resale mechanics for existing holders. The filing discloses $0.00000002 par value for each of up to 226,000,000 shares of common stock and 100,000 shares of undesignated preferred stock. As of June 30, 2025, 102,513 common shares are issuable upon exercise of warrants at $6.80 per share, 869,168 shares are issuable upon exercise of options with a weighted-average exercise price of $32.85, 920,737 shares are reserved under the 2008 Omnibus Plan, and 169,698 shares are reserved under the 2021 Inducement Plan. The filing lists a range of permitted sale methods for selling stockholders including brokerage, block trades, privately negotiated transactions, option/hedging arrangements, and other lawful methods. It also describes a three-year restriction on certain transfers by any stockholder who becomes an interested stockholder (owner of 15% or more voting stock) unless specific board approvals or exceptions apply. The filing cross-references the company’s Annual Report for the fiscal year ended June 30, 2025 and several Current Reports filed in July–September 2025.
Lite Strategy, Inc. (LITS) director Lee Charles Benjamin received a non‑derivative grant of 10,000 stock options on 10/03/2025 with an exercise price of $2.56. The option is a stock option exercisable into 10,000 shares of common stock and expires on 10/03/2035. The grant vests in 36 equal monthly installments, with the first monthly installment vesting one month after the grant, subject to continued service through each vesting date. Following the reported transaction the reporting person is shown as beneficially owning the 10,000 underlying shares on a direct basis. The filing was submitted under power of attorney by Justin J. File and dated 10/06/2025.
Flynn James P, a director of Lite Strategy, Inc. (ticker LITS), reported a purchase of 10,000 shares of the company's common stock on 09/30/2025. The filing shows a weighted-average purchase price of $2.543 per share, with individual transactions priced between $2.51 and $2.58. After the acquisition, Flynn beneficially owned 17,900 shares.
The Form 4 was submitted on 10/02/2025 and signed by an attorney-in-fact. The reporting person offers to provide details on the split of share counts by price within the disclosed range upon request.